company background image
NYMX.F logo

Nymox Pharmaceutical OTCPK:NYMX.F Stock Report

Last Price

US$0.40

Market Cap

US$37.3m

7D

-19.9%

1Y

-6.9%

Updated

19 Feb, 2024

Data

Company Financials

Nymox Pharmaceutical Corporation

OTCPK:NYMX.F Stock Report

Market Cap: US$37.3m

NYMX.F Stock Overview

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally.

NYMX.F fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health1/6
Dividends0/6

Nymox Pharmaceutical Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Nymox Pharmaceutical
Historical stock prices
Current Share PriceUS$0.40
52 Week HighUS$1.28
52 Week LowUS$0.12
Beta0.29
1 Month Change-14.52%
3 Month Change-59.96%
1 Year Change-6.88%
3 Year Change-87.21%
5 Year Change-81.11%
Change since IPO-93.69%

Recent News & Updates

Recent updates

Nymox gets FDA feedback on NDA resubmission for lead asset

Sep 13

Is Nymox Pharmaceutical (NASDAQ:NYMX) In A Good Position To Deliver On Growth Plans?

Aug 17
Is Nymox Pharmaceutical (NASDAQ:NYMX) In A Good Position To Deliver On Growth Plans?

NYMOX stock down 7.2% after receiving non-compliance letter from Nasdaq

Jul 14

Nymox to file for Fexapotide approval by mid-September

May 06

Nymox under pressure on $8M private placement

Apr 28

What You Need To Know About Nymox Pharmaceutical Corporation's (NASDAQ:NYMX) Investor Composition

Mar 01
What You Need To Know About Nymox Pharmaceutical Corporation's (NASDAQ:NYMX) Investor Composition

Shareholder Returns

NYMX.FUS BiotechsUS Market
7D-19.9%0.6%-0.2%
1Y-6.9%4.4%20.5%

Return vs Industry: NYMX.F underperformed the US Biotechs industry which returned 4.8% over the past year.

Return vs Market: NYMX.F underperformed the US Market which returned 20.5% over the past year.

Price Volatility

Is NYMX.F's price volatile compared to industry and market?
NYMX.F volatility
NYMX.F Average Weekly Movement25.8%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.1%

Stable Share Price: NYMX.F's share price has been volatile over the past 3 months.

Volatility Over Time: NYMX.F's weekly volatility (26%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1989n/aPaul Averbackhttps://nymox.com

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure.

Nymox Pharmaceutical Corporation Fundamentals Summary

How do Nymox Pharmaceutical's earnings and revenue compare to its market cap?
NYMX.F fundamental statistics
Market capUS$37.34m
Earnings (TTM)-US$4.87m
Revenue (TTM)n/a

0.0x

P/S Ratio

-7.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NYMX.F income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$4.87m
Earnings-US$4.87m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.052
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did NYMX.F perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.